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Introduction
Autosomal dominant cerebellar ataxia is the term used for a group of heterogeneous conditions which can be subdivided into three types based on clinical features (Harding, 1982) . In ADCA type I, cerebellar ataxia is variably associated with extracerebellar symptoms, such as pyramidal tract or extrapyramidal signs, ophthalmoplegia, peripheral neuropathy or dementia (Harding, 1982) . At present, four different gene loci responsible for ADCA type I have been identified: SCA1 (Yakura et ai, 1974; Zoghbi et al., 1991) ; SCA2 (Gispert et al., 1993) ; Machado-Joseph disease (MJD, SCA3) (Takiyamaera/., 1993; Stevanin etal., 1994) ; SCA4 (Gardner et al., 1994) . Among these, spinocerebellar ataxia type 1 and MJD have been both demonstrated to be associated with the © Oxford University Press 1996 expansion of the unstable trinucleotide CAG repeats Kawaguchi et al., 1994) . Autosomal dominant cerebellar ataxia type II, characterized by macular degeneration, is clinically and genetically distinct from ADCA type I (Benomar et al., 1994 (Benomar et al., , 1995 Enevoldson et al., 1994) .
In contrast, ADCA type III remains as 'pure' cerebellar ataxia, there being no clinical evidence for multisystem involvement (Harding, 1982) . Neuropathological findings support the clinical characteristics demonstrating the restricted degeneration in the cerebellar cortex mostly with involvement of the inferior olive (Eadie, 1991) . Although available data indicate that the incidence of ADCA type III is relatively low in Europe (Harding, 1982; Polo et al., 1991) , it constitutes ~10% of all patients with spinocerebellar degeneration in Japan (Hirayama et al., 1994) .
The gene responsible for ADCA type III remains unknown (Frontali et al., 1992; Giunti et al., 1994 Giunti et al., , 1995 . Also, clinical and genetic correlations have not yet been investigated in a large series of patients with ADCA type III. It is important to clarify whether anticipation (i.e. earlier ages of onset with generally more severe clinical phenotype in successive generations) is seen in ADCA type III, since this phenomenon is commonly observed in other ADC As Benomar et al., 1994; Takiyama et al., 1994) , as well as other inherited neurodegenerative diseases associated with expansion of trinucleotide repeats (La Spada et al., 1994) .
Recently, a gene that causes ADCA type III has been mapped for the first time to the centromeric region of chromosome 11 (SCA5) (Ranum et al., 1994) . This discovery enabled us to investigate whether clinical and genetic heterogeneity exists in ADCA type III.
In this paper we delineate clinical characteristics of our patients with ADCA type III, and show that ADCA type III is clinically and genetically a heterogenous condition.
Patients and methods

Clinical investigations
The index patients were admitted for complete neurological work-up including standard blood tests, brain MRI, neurophysiological recordings and neuropsychological tests. Other at-risk family members were traced and clinically examined by the same neurologists (K.I. and H.M.). The disability due to ataxia was rated in four classes (A-D) according to the scale used in ADCA type I (Diirr et al., 1993) . In most families, patients aged over 70 years or with long duration of illness were also investigated on MRI.
Forty-one patients from eight families fulfilled the diagnostic criteria for ADCA type III ( Fig. 1 ): (i) progressive cerebellar ataxia; (ii) family history compatible with autosomal dominant inheritance;, (iii) no clinical (i.e. neurological, neuroradiological and electrophysiological) evidence for multisystem degeneration. Seven out of eight families were the original residents in Ibaraki Prefecture, a suburb of Tokyo. The remaining family (Pedigree 2) was from Oita Prefecture in Kyushu Island. By linkage or direct gene analyses, SCA1, SCA2, MJD/SCA3 and SCA4 have been excluded for these families (data not shown).
The age of onset was determined from information obtained from the affected patients and/or their close family members. To examine the evidence for anticipation, differences in age of onset were calculated in 23 parent-offspring pairs, in whom we were able to obtain highly reliable information on the age of onset. Data from five well-documented patients who died before the study were also included to examine the age of onset and disease duration.
Statistical analysis was performed with non-parametric 
Genetic analysis
Blood samples were obtained with informed consent from 85 individuals including 41 affected patients, and high molecular weight genomic DNA was extracted using a standardized procedure (Sambrook et al., 1989) . The locus for SCA5 was studied with four microsatellite markers (Dl 1S905, Dl 1S903, GATA2A01, D11S913) spanning a 13-cM region of the SCA5 locus on chromosome 11 (Gyapay et al., 1994; Ranum et al., 1994) . The distances between these markers were reported as follows: p telomere-DllS905-3cM-DHS903-2cM-GATA2A01-8cM-DllS913-q telomere (Gyapay et al., 1994; Ranum et al., 1994) . Genotyping was performed by using the automated DNA sequencer system [Automated Laser Fluorescence (A.L.F.™) DNA Sequencer II, Pharmacia Biotechnology] ( Ansorge et al., 1987; Aoki et al., 1994) . For each primer pair, one of the primers was end-labelled with fluorescein isothiocyanate. The polymerase chain reaction was carried out in a 25-|ll reaction volume, containing 125 ng of DNA, 2.5 pmol of each primer, 100 (iM of each deoxynucleoside triphosphate, 10 mM Trishydrochloric acid, pH 8.4,50 mM potassium chloride, 1.5 mM magnesium chloride and 0.5 unit of Taq DNA polymerase (Takara, Japan). Samples were processed through initial denaturation at 94°C for 3 min, 30 cycles of denaturation (94°C for 30 s), annealing (55°C for 30 s) and elongation (72°C for 3 min), followed by a final elongation at 72°C for 5 min. Of each polymerase chain reaction product 1.5 (il was mixed with 4.5 (il of formamide loading buffer and 0.75 \\\ of each size marker (Loading Dye®, Sizer®l 00 and Sizer® 300; Pharmacia Biotechnology), denatured at 80°C for 5 min and separated in 7% polyacrylamide/8 M urea gels. Genotypes were finally determined with computer software (Fragment Manager®; Pharmacia Biotechnology) by comparison with an Ml3 sequencing ladder (AutoRead®, Pharmacia Biotechnology) (Fig. 2) . By this method, highly reproducible data were quickly obtained without using radioisotopes.
Pairwise and multipoint lod scores were calculated using MLINK and LINKMAP programs from the computer package LINKAGE(versions.i) (Lathrop etal., 1984) . Five age-dependent penetrance classes were established, based on the cumulative age of onset curve (Ott, 1991) , with a maximal penetration of 100% over age 70 years. Allele frequencies for the markers were calculated from 42 unrelated neurologically normal Japanese individuals. The disease gene frequency was estimated at 1 in 10 000. Recombination fractions for men and women were assumed to be equal. The heterogeneity analysis within our eight families was carried out using program HOMOG (Ott, 1991) . 
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n El 1AA1 Fig. 1 Pedigrees of families studied. Circle = female; square = male; filled symbols = affected; oblique line = deceased. *Subjects who were sampled. In Pedigrees (P) 4, 5 and 8, the affection status of the first generation is left unknown, because these individuals had died earlier and did not reach the age-of-onset in their families. 
Results
Clinical characteristics of eight families with ADCA type III Age of onset, anticipation and disease duration
Of the 41 affected individuals, 23 were male and 18 were female. At examination, the mean age±SD was 61.8±13.1 years and the duration of the disease was 15.4± 11.0 years. Highly reliable information on the age of onset was obtained for 36 living (Table 1) and five deceased patients. The overall mean age of onset was 46 ±9.0 years, ranging from 32.5 ±9.4 years in Pedigree 3 to 58.4±4.8 years in Pedigree 2.
Individual and cumulative distribution of age of onset in the 41 patients revealed that most patients (83%) became symptomatic over 40 years (Fig. 3) . Sex of the affected individuals did not influence the age of onset. The segregation ratio reached 0.5, suggesting complete penetrance.
In the analysis of ages of onset in parent-offspring pairs (n = 23), great variability was noted (Fig. 4) . The onset was earlier in offspring in 14 pairs and earlier in a parent in four pairs. In the remaining five parent-offspring pairs, onsets were at the same age. The overall mean difference between the ages of onset in parents and their offspring was 3.2±7.7 years younger in the offspring, suggesting that the phenomenon of anticipation is statistically significant (P = 0.0386), but is mild. Among eight families, dramatic anticipation was evident in one family (Pedigree 3; 13.8±9.8 years) (Fig. 4) . For the remaining seven families, anticipation was not proved to be statistically significant (1.0±5.1 years). The effect of parental sex on anticipation was not statistically significant: the average decrease in the age of onset of offsprings was 3.9±8.5 years for maternal transmission (n = 15), while the decrease was 1.9±6.0 years for paternal transmission (n = 8). However, the two dramatic anticipations both seen in Pedigree 3 (Patients III-2 and III-7) were transmitted through the same mother (Patient II-2).
The mean age at death was 80.5±7.8 years (/> = 5, range 81-86 years), and the mean total duration of illness in these patients was 29.8±9.3 years. In four out of five patients, the direct cause of death was recurrent pneumonia after long periods being bedridden. Since no patients in successive generations had deceased, intergenerational differences in the total duration of illness were not ascertained.
Clinical features
The clinical features are summarized in Table 1 . Gait ataxia was the first presenting symptom of all patients (100%), and was invariably the most prominent feature throughout the illness. Other frequent neurological symptoms were all ascribed to cerebellar disturbances: cerebellar speech with dysarthria (41 out of 41), generalized muscle hypotonia (41 out of 41), and limb ataxia prominent in lower extremities (37 out of 41). Mild terminal oscillation was also frequently seen in the finger-nose-finger test (35 out of 41). All of these signs tended to be more prominent in advanced stages than in earlier stages. Horizontal gaze nystagmus with saccadic eye movement was noted in 25 patients (60.9%). The patients without this nystagmus were mostly (11 out of 13) within 10 years after onset, suggesting that horizontal gaze nystagmus could be absent at an earlier stage (P < 0.001). Tendon reflexes were normal, or slightly brisk 
Decreased vibration sense ND = not determined. *Disability was graded according to Diirr et al. (1993). mostly in the patellar tendon: they were never decreased nor pathologically exaggerated even at an advanced stage. There was no clinical feature significantly different between generations.
Pyramidal tract signs (extensor plantar response or spasticity) or extrapyramidal features, ophthalmoplegia, muscle weakness or amyotrophy were not observed, and vibration sense was mildly decreased only in an 85-year-old aged patient (Pedigree 2, III-2). Intellectual impairment was not evident even in aged patients over 70 years. Sphincteric impairment and dysphagia were both inconspicuous even at an advanced stage.
The progression of cerebellar ataxia was uniformly slow, constituting another clinical characteristics of our families. Mean duration of the disease at each disability stage was: A = 3.6±1.0 years (n = 6); B = 8.3±3.7 years (n = 12); C = 22.2±3.6 years (n = 10); D = 29.1 ±7.5 years (n = 8). Within 20 years after onset, 18 out of 20 patients (90.0%) were still able to walk independently, and nine out of 16 patients (56.3%) at more than 20 years after onset could walk with assistance. Two patients with earlier onset (Pedigree 3, III-2 and III-7) did not show different clinical phenotype nor rapid disease progression, since these patients were still able to walk even 13 and 25 years after onset.
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Age of onset of offspring minus age of onset of parent (years) Fig. 4 Histogram showing the distribution of the difference in the age of onset in 23 parent-offspring pairs. Note that two pairs from maternal transmissions show significantly earlier onset in offsprings (between -25 and -21 years).
Fig. 5 T r weighted MRIs (TR 500 ms; TE 20 ms) of a patient (Pl-IV-9) with ADCA type III. Left: on the mid-sagittal section, the cerebellar atrophy is evident particularly in the superior and middle aspect of the vermis, whereas the tonsil is relatively spared. Also note that the brainstem and the cerebrum are preserved. Right: the axial section through the upper parts of the pons and the cerebellum. The vermis is markedly atrophic and the cerebellar sulci are moderately widened, whereas the pons appears to be spared.
Neuroradiological features
Brain MRI demonstrated cerebellar atrophy in all 22 patients examined; however, the brainstem was spared (Fig. 5) . In the cerebellum, atrophy was always predominant in the superior aspect, and the vermis was more severely involved than the hemisphere. Thus, the superior and middle vermis (the central lobule, culmen, declive, folium and tuber vermis) was always severely involved, while the tonsil and the medial part of the biventral lobule were almost spared in most patients.
The cerebrum was also spared except that a mild and agerelated cortical atrophy was seen in a few aged patients (« = 4). 
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Linkage analysis for SCA5 locus
The results of pairwise linkage analysis of eight families each with of the four markers are shown in Table 2 . For all markers examined, negative lod scores were generated in most families. A few families, however, showed lod scores not conclusive for exclusion. For example, lod scores in six out of eight families (Pedigrees 1, 2, 4, 6, 7 and 8) for GATA2A01 were between -0.82 and 0.42. However, the heterogeneity test by program HOMOG did not suggest genetic heterogeneity within eight families for either markers (data not shown). Thus, linkage was highly unlikely for either markers examined. Multipoint analyses revealed significantly negative lod scores (below -2) in a 48.4-cM interval between 18.8 cM telomeric to D11S905 and 16.6 cM telomeric to D11S913. These results led to the conclusion that SCA5 is not the locus responsible for the families we studied.
Discussion
The present study permitted two important observations. First, we delineated a clinical picture of eight families consistent with ADCA type III (Harding, 1982) . Clinical characteristics of the eight families are summarized as follows: (i) pure cerebellar syndrome without clinical evidence for other system involvement; (ii) typical disease onset in forth decade or later; (iii) mild but not dramatic anticipation, except in one family which showed striking anticipation through maternal transmission; (iv) a slowly progressive disease progression toward inability with a normal life expectancy. Secondly, we showed by linkage analysis on SCA5 locus that there is a non-allelic genetic heterogeneity in ADCA type III.
Detailed clinical descriptions of ADCA type III have been previously made (Zee et ai, 1976; Frontali et al., 1992) , and also clinico-pathological investigations including probable families have been reported (Hall et al., 1941 (Hall et al., , 1945 Weber and Greenfield, 1942; Richter, 1950; Hoffman et al., 1971) . Recently, Ranum et al. (1994) described a 10-generation kindred with ADCA type III and mapped the gene locus to chromosome 11 (SCA5). As far as we are concerned, however, this is the first study that dealt with a large number of families with ADCA type III.
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In our series of patients, gait ataxia was invariably the presenting symptom, and cerebellar speech with dysarthria, generalized muscle hypotonia and limb ataxia were also frequent symptoms. Similar observations are also described in previous studies (Hall et al., 1941 (Hall et al., , 1945 Richter, 1950; Hoffman et al., 1971) . Horizontal gaze nystagmus, which is also regarded as a cerebellar sign (Zee et al., 1976; Moschner et al., 1994) , was often absent or not evident in earlier stage. Therefore, it is conceivable that the presence of horizontal gaze nystagmus indicates progression of the cerebellar degeneration. However, this assumption needs to be reevaluated, since previous studies did not find a significant correlation of oculomotor findings and the severity or duration of illness (Zee et al., 1976; Moschner et al., 1994) .
Pure cerebellar ataxia in our patients is also supported by the MRI finding: cerebellar atrophy without brainstem or cerebral involvement was confirmed in all patients examined. In the cerebellum, the superior and middle vermis constantly showed the severest atrophy, while the tonsil and medial biventral lobule were almost spared. Similar observations are also described in previous studies dealing with smaller numbers of patients (Klockgether et al., 1990; Plaitakis et al., 1992) .
In addition to the pure cerebellar symptom, indolent and uniform progression of the disease regardless of generations was another important feature of our families. In accord with our observation, generally slow progression and somewhat uniform clinical manifestations were also observed in other families with ADCA type III (Hall et al., 1941 (Hall et al., , 1945 Richter, 1950; Hoffman et al., 1971; Frontali et al., 1992) . Of note is that earlier disease onset in successive generations is also described in these families. In contrast, more rapid progression or different clinical phenotypes in younger generations are commonly seen in both ADCA type I and type II (Diirr et al., 1993; Enevoldson et al., 1994; Jodice et al., 1994; Takiyama et al., 1994) . Therefore, an indolent and uniform clinical course as well as pure cerebellar ataxia seemed to be an important feature in differentiating ADCA type III from other ADCAs.
Whether or not clinical heterogeneity exists in ADCA type III has not been clearly defined. However, comparing SCA5 (Ranum et al., 1994) with the present families, several clinical differences are found. First, typical age of onset in the SCA5 family was in the third to fourth decade, while the age of onset was mostly in the fourth decade or later in the present families. Unfortunately, no exact mean for the age of onset was described in the SCA5 family, preventing the assessment of statistical difference between SCA5 and our families. Secondly, dramatic anticipation was observed in the SCA5 family, whereas seven out of eight families (except Pedigree 3) in this study were not proved to show significant anticipation. Obviously, further follow-up including successive generations is needed before precluding anticipation in these seven families. At present, however, no one in the family members in younger generations has developed ataxic symptoms. It is also possible that there has been an ascertainment bias in Pedigree 3. Notably, the SCA5 locus was also excluded for this family. Thirdly, bulbar paralysis and pyramidal tract involvement were observed in patients with much earlier onset (10-18 years) in the SCA5 family. However, these symptoms as well as such juvenile onset were not observed in the present families. Since genetic heterogeneity was demonstrated between SCA5 and the present families, these clinical differences might be the important points to differentiate the two distinct disorders.
Clinical differences could also be found among other families with ADCA type III. One family showed earlier disease onset (30±14.6 years) with consistently hypoactive tendon reflexes (Frontali et al., 1992) . On the other hand, many others showed later disease onset (usually over 40 years) usually with normal tendon reflexes (Hall et al., 1941 (Hall et al., , 1945 Weber and Greenfield, 1942; Richter et al., 1950; Hoffman et al., 1971; Zee et al., 1976; Harding, 1982) . Consistent with this view, one group reported that 13 out of 24 families with ADCA type III showed earlier onset (between the second and fourth decade), while the remaining 11 families showed later onset (over 40 years) . It is of interest that the distal loss of vibration sense or pyramidal tract signs were occasionally found in their study. These clinical differences might imply further clinical and genetic heterogeneity in ADCA type III.
Striking anticipation has been discovered to be associated with trinucleotide repeat expansion in various neurological disorders, including SCA1 Jodice et al., 1994) and MJD (Takiyama et al., 1995) . In our series of patients, most striking anticipation was observed through maternal transmission, which was similar to SCA5 (Ranum et al., 1994) . However, dramatic anticipation was still a rare event in the present families, suggesting that a different mechanism other than an unstable trinucleotide repeat might be involved. Identifying the underlying gene defect(s) would not only resolve this issue but also offer a new insight in the molecular pathophysiology and classification of ADCA type III.
